Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance
Open accessThe DOI matches its Crossref record; 99 of the 100 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder in women of reproductive age. Its heterogeneous clinical presentation is characterized by hyperandrogenemia, reproductive changes, polycystic ovary morphology, and insulin resistance (IR). The primary pathophysiological process in its multifactorial etiology has not yet been identified. However, the two most proposed core etiologies are the disruption of insulin metabolism and hyperandrogenemia, both of which begin to intertwine and propagate each other in the later stages of the disease. Insulin metabolism can be viewed as the interconnectedness of beta cell function, IR or insulin sensitivity, and insulin clearance. Previous studies of insulin metabolism in PCOS patients have yielded conflicting results, and literature reviews have focused mainly on the molecular mechanisms and clinical implications of IR. In this narrative review, we comprehensively explored the role of insulin secretion, clearance, and decreased sensitivity in target cells as a potential primary insult in PCOS pathogenesis, along with the molecular mechanism behind IR in PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The insulin resistance in PCOS might also occur independently of body weight, due to inherited post-receptor defects in insulin signalling that affects metabolism and mitotic pathways, not only in classic insulin target tissues, such as skeletal muscle, liver, and adipose tissue, but also in the non-classical target tissues, such as pituitary and ovary [12, 16].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hyperinsulinemia is closely involved in key steps of the pathogenesis of PCOS and hyperandrogenism [9–12].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Introduction to the human gut microbiota
Thursby, E., & Juge, N. (2017) · Biochemical Journal · doi:10.1042/bcj20160510 · Cited by 3,600
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028 · cited 1×
“Thus, insulin-resistant tissues exhibit decreased responsiveness and sensitivity to insulin stimulation, whereas this effect is more pronounced in PCOS patients than in obese patients [60,61].”
BackgroundInsulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458 · cited 1×
“The clinical presentation of PCOS patients is influenced by other insulin related systemic effects through modulation of the luteinizing hormone pulse amplitude, stimulation of adrenal androgen secretion, and the suppression of hepatic sex hormone binding globulin production, which increases the amount of free testost…”
BackgroundAzziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005 · cited 2×
“However, with disease progression, relative or absolute insulin deficiency presents as prediabetes or T2D in the predisposed patients [10].”
BackgroundMethodProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Correlation of Hyperandrogenism with Hyperinsulinism in Polycystic Ovarian Disease*
BURGHEN, G. A., GIVENS, J. R., & KITABCHI, A. E. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-50-1-113 · Cited by 919 · cited 1×
“The coexistence of IR and PCOS was first described in 1980, when it was demonstrated that hyperandrogenism correlates with hyperinsulinism in women with PCOS [7].”
BackgroundInsulin Degradation: Progress and Potential*
Duckworth, W. C., Bennett, R. G., & Hamel, F. G. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0349 · Cited by 871 · cited 1×
“MCRI is determined by the efficiency of the insulin degradation process, which involves the internalization of the insulin-receptor complex and is followed by insulin degradation in the cytoplasm, carried out by insulin-degrading enzyme and other lysosomal enzymes [84,85].”
BackgroundChen, Z.-J., Zhao, H., He, L., Shi, Y., Qin, Y., Shi, Y., Li, Z., You, L., Zhao, J., Liu, J., et al. (2011) · Nature Genetics · doi:10.1038/ng.732 · Cited by 782
Cited by
Yang, J., & Chen, C. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0342 · Cited by 169
Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome
Deng, H., Chen, Y., Xing, J., Zhang, N., & Xu, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1470283 · Cited by 170
Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome
Wang, K., & Lǐ, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1191759 · Cited by 127
“Obesity may aggravate IR: overall, it promotes insulin secretion while repressing its clearance and degradation (11).”
BackgroundMacrophages: a double-edged sword in female reproduction and disorders
Park, M., Kim, Y. S., & Song, H. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01392-6 · Cited by 82
“This disturbed condition can affect glucose uptake in the endometrium and cause fertility failure in these women 52 .”
Salehi, S., Allahverdy, J., Pourjafar, H., Sarabandi, K., & Jafari, S. M. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10223-5 · Cited by 51
Fang, Y., Ding, H., Li, T., Zhao, X., Luo, D., Liu, Y., & Li, Y. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01528-8 · Cited by 42
“Insulin resistance is the core pathological mechanism involved in the development of PCOS [41].”
BackgroundZhang, Z., Shi, C., & Wang, Z. (2023) · Nutrients · doi:10.3390/nu15132833 · Cited by 38
“DMBG is a common insulin sensitizer that can control the blood sugar of type 2 diabetes, alleviate the clinical symptoms of PCOS patients, and reduce LH levels and hyperandrogenism.”
BackgroundInfluentialLiraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02084-6 · Cited by 29
“The insulin resistance in PCOS might also occur independently of body weight, due to inherited postreceptor defects in insulin signalling that affects metabolism and mitotic pathways, not only in classic insulin target tissues, such as skeletal muscle, liver, and adipose tissue, but also in the non-classical target ti…”
BackgroundPanda, S. P., Kesharwani, A., Singh, G. D., Prasanth, D., Vatchavai, B. R., Kumari, P. V. K., Panda, S. K., & Mallick, S. P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102086 · Cited by 27
Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects
Mastnak, L., Herman, R., Ferjan, S., Janež, A., & Jensterle, M. (2023) · Life · doi:10.3390/life13112124 · Cited by 40
“Therefore, lower SHBG levels lead to higher levels of free testosterone [9,13,16].”
BackgroundSelf-citationKhatun, M., Lundin, K., Naillat, F., Loog, L., Saarela, U., Tuuri, T., Salumets, A., Piltonen, T., & Tapanainen, J. S. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10627-w · Cited by 23
“IR and hyperinsulinemia lead to decreased levels of sex hormone-binding globulin (SHBG), which in turn cause an increase in free androgens and adverse metabolic profiles [ 19, 20].”
BackgroundDema, H., Paska, A. V., Kouter, K., Katrašnik, M., Jensterle, M., Janež, A., Oblak, A., Škodlar, B., & Bon, J. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45040178 · Cited by 24
“Obesity increases insulin resistance (IR) [6], which, together with impaired insulin sensitivity and beta cell function, leads to accelerated development of prediabetes and type 2 diabetes in 30–45% of patients [7].”
BackgroundSelf-citationLittle, P. J., Offermanns, S., Cho, H., Liu, Z., Yang, P., Su, Q., Wade, H., Yang, W., Kamato, D., Cohen, N. D., et al. (2026) · iNew Medicine · doi:10.1002/inm3.70028 · Cited by 27
Khobragade, N. H., Sheth, D. B., Patel, C. A., Beladiya, J., Patel, S. P., & Dalal, M. (2024) · Steroids · doi:10.1016/j.steroids.2024.109455 · Cited by 14
Abudawood, M. (2025) · Human & Experimental Toxicology · doi:10.1177/09603271251342280 · Cited by 9
“20 Based on these perspectives, REE exposure may be a key factor in PCOS etiology through oxidative stress.”
Ranneh, Y., Hamsho, M., Shkorfu, W., Terzi, M., & Fadel, A. (2025) · Nutrients · doi:10.3390/nu17152436 · Cited by 11
“Furthermore, the coexistence of excess body weight (BW) and insulin resistance (IR) creates a reciprocal relationship that exacerbates the clinical presentation of PCOS [9,10].”
Yu, S., Hou, C., Zhang, X., & Wei, Z. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149782 · Cited by 9
Janež, A., Herman, R., Poredoš, P., Mikhailidis, D. P., Blinc, A., Šabović, M., Studen, K. B., Jezovnik, M. K., Schernthaner, G.-H., Anagnostis, P. G., et al. (2023) · Current Vascular Pharmacology · doi:10.2174/0115701611269146230920073301 · Cited by 11
Self-citationTosi, F., Lando, M. G., Rosmini, F., Lucarini, F., Fiorio, V., Zanolin, M. E., Fiers, T., Kaufman, J., & Moghetti, P. (2025) · Human Reproduction · doi:10.1093/humrep/deaf114 · Cited by 7
Genetic–epigenetic targets for PCOS-associated diabesity
Sharma, A. K., Mukherjee, M., Akhtar, M. S., Orayj, K. M., Farooqui, S., & Khan, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104373 · Cited by 5
From root to Recovery: The role of herbs in polycystic ovary syndrome management
Zafar, N.-U.-A., Qureshi, R., Siddiqa, A., Naqvi, S. A. M., Waheed, F., Mashwani, Z., Ali, A., Ramírez, K. A. H., Medina‐Pérez, G., Peláez-Acero, A., et al. (2025) · Steroids · doi:10.1016/j.steroids.2025.109606 · Cited by 6
Recent advances in reprogramming lactate metabolism in polycystic ovary syndrome
Xu, J., Chen, W., Huang, M.-N., Zheng, L., Huang, S.-Y., Lin, S., & Shi, Q. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01797-x · Cited by 5
“Elevated insulin levels can disrupt ovarian function and sinus follicle development by affecting the HPO axis [20].”
Neurological study on the effect of CeNPs and/or La Cl3 on adult male albino rats
Abdel-Rahman, M., Elmasry, H. M., Ahmed-Farid, O. A.-H., Hegazy, S. M., & Rezk, M. M. (2023) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2023.127323 · Cited by 5
Clinical significance and biological roles of lncRNA CTBP1-AS in polycystic ovary syndrome
Qin, L., Tian, C., Huang, L.-Y., Xiao, Q., Ling, S., Wei, J., Huang, B., Li, L., & Luo, X. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01571-5 · Cited by 4
Kumari, R., Muneshwar, K. N., Pathade, A. G., & Yelne, S. (2023) · Cureus · doi:10.7759/cureus.44752 · Cited by 5
Low serum hepcidin levels in women with polycystic ovary syndrome: evidence from meta-analysis
Nong, J., Li, H., Yang, Y., Qing-hong, L., Sun, Y., Yin, Q., & Hongying, H. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2024.2375568 · Cited by 6
“In addition, IR, along with hyperinsulinemia and hyperan-drogenism, is considered the main cause and primary endocrine feature of PCOS; these conditions interact when it comes to in the occurrence and progression of the disorder [2,32].”
Wei, J., Liu, A., Fan, Z., Peng, X., Lou, X., Lu, X., & Hu, J. (2025) · Foods · doi:10.3390/foods14071142 · Cited by 3
Research progress on insulin resistance in polycystic ovary syndrome
Qi, Y.-B., Yi, P., & Fu, X. (2025) · Reproductive and Developmental Medicine · doi:10.1097/rd9.0000000000000131 · Cited by 5
Zhang, Y., Chen, M., Zhou, Z. G., Guo, Y., Zheng, L., Yu, Y., Liu, J., Zhou, Y., Lu, H., Yao, S., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1517934 · Cited by 3
Olaniyi, K. S., Bebenimibo, T., Areloegbe, S. E. J., & Emereonye, C. F. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117599 · Cited by 2
Wang, K.-Y., Yang, T., Ding, Y.-F., Zeng, A., Li, Y., & Qiang, J.-W. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1652954 · Cited by 3
“Clinically, PCOS is characterized by menstrual irregularities, hirsutism, obesity, hyperinsulinemia, and hyperandrogenism (3).”
Hou, Z., Hua, Y., Gao, S., Si, F., Wang, S., Jin, C., He, Z., Zhang, Z., & Chen, Y. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02017-w · Cited by 4
“…models often address hyperandrogenism and IR as primary, parallel drivers of PCOS pathology, they frequently fail to account for the rising evidence of systemic low-grade inflammation and immune dysregulation in the syndrome, particularly the pervasive role of the gut-metabolic axis [2, 16, 17].”
Nancy Lima Christy, S., & Nithyakalyani, S. (2023) · Computer Methods in Biomechanics & Biomedical Engineering · doi:10.1080/10255842.2023.2252957 · Cited by 2
“Herman et al. (2023) Explored the secretion, signalling, and elimination of insulin in females diagnosed with PCOS.”
BackgroundResearch Progress of Polycystic Ovary Syndrome and Metabolic Syndrome
马, 宁. (2023) · Medical Diagnosis · doi:10.12677/md.2023.133058 · Cited by 2
Cao, Y., Wang, W., Song, X., Wen, Q., Xie, J., & Zhang, D. (2024) · Genes · doi:10.3390/genes15040494 · Cited by 4
Obesity, ovarian GLUT4 expression, and reproductive dysfunction: Insights from Zucker fatty rat
León, M. C. P. Y. C., Trujillo, A., Castelán, F., & Xochitemol-Nava, M. (2025) · Reproductive Biology · doi:10.1016/j.repbio.2025.101025 · Cited by 2
100 Years of Insulin: A Historical Perspective
Pinto, G. B., Itabaiana, I., de Magalhães, J. L., & Antunes, A. M. D. S. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266315941241127092613 · Cited by 1
Nutritional ketosis as therapeutic regimen for metabolic disorders: Perspectives and challenges
Ul‐Haq, I., Saleem, K., Iftikhar, H., & Abdi, G. (2025) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2025.101981 · Cited by 3
Shnawa, B. H., Jalil, P. J., Al-Ali, S., Qadir, R. A., Raswl, R. H., Anwar, K. I., & Ahmed, M. H. (2025) · Comparative Clinical Pathology · doi:10.1007/s00580-025-03673-y · Cited by 1
“Insulin metabolism involves the coordination of beta cell function, insulin resistance or insulin sensitivity and insulin clearance (Herman et al. 2023).”
Upadhyay, S., Mazumder, A., & Das, S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128382284250822045319 · Cited by 1
Polycystic ovary syndrome and cardiometabolic risk: a perspective on women's heart health
Joksimović, J., Jovic, N., Muric, M. D., & Jakovljevic, V. L. (2025) · Current Opinion in Physiology · doi:10.1016/j.cophys.2025.100869 · Cited by 1
Polycystic Ovary Syndrome May Be Associated With a Novel Mitochondrial tRNAAsp Mutation
Ding, Y., Yu, X., Xu, J., Zhang, C., & Leng, J. (2025) · Human Mutation · doi:10.1155/humu/6663471 · Cited by 1
“Because insulin signaling relied on pathways such as PI3K/PKB and MAPK/ERK, mitochondrial dysfunction-induced interference with these cascades may contribute to IR and PCOS pathogenesis [45].”
Yu, J., Pan, Z., Sun, M., Li, Y., Wang, Y., Gu, F., Feng, X., Kuang, H., & Hou, L. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2579046 · Cited by 1
“By promoting increased ovarian androgen production and reducing sex hormone-binding globulin levels, IR contributes to hyperandrogenism and establishes a vicious cycle that exacerbates endocrine and metabolic dysfunction [4,5].”
Wei, J., Fan, Z., Deng, Y., Pan, K., Shi, R., Hu, J., & Liu, B. (2026) · Nutrients · doi:10.3390/nu18060973 · Cited by 1
Waqar, M. A., Mubarak, N., & Khan, R. (2026) · Reproductive Sciences · doi:10.1007/s43032-026-02087-7 · Cited by 3
“3 [68, 69].”
Mousavi, M. A., Naz, M. S. G., Noroozzadeh, M., Azizi, F., & Tehrani, F. R. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70322 · Cited by 1
“Abnormalities in insulin secretion, its signalling, and clearance have been observed among women with PCOS [16].”
Modulation of PON-1 by acetate reverses hepatic dysmetabolism in experimentally induced PCOS
Olaniyi, K. S., & Areloegbe, S. E. J. (2024) · Comparative Clinical Pathology · doi:10.1007/s00580-024-03553-x · Cited by 1
“The observable traits of this PCOS include hyperandrogenism appearing with hirsutism in most cases and anovulation/oli-gomenorrhea, as well as multiple cysts in the ovaries under ultrasound evaluation (Deswal et al. 2020; Herman et al. 2023).”
Lin, R., Wang, J., Fu, W., Tuo, S., Ran, J., Shao, Y., & Shao, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-3878317/v1 · Cited by 1
Khmil, S. V., & Калник, А. А. (2024) · Актуальні питання педіатрії акушерства та гінекології · doi:10.11603/24116-4944.2024.1.14741
Khmil, S. V., & Правак, Ю. Б. (2024) · Актуальні питання педіатрії акушерства та гінекології · doi:10.11603/24116-4944.2024.1.14751
Assessing Insulin Clearance in Mice via In Situ Liver Perfusion
Fu, Z., Wang, Y., Chen, L., Hou, Z., Gong, Y., & Zhou, H. (2024) · Journal of Visualized Experiments · doi:10.3791/66730
Disorder-Related Sex Steroid Hormonal Production: Polycystic Ovarian Syndrome
Sentosa, I. G. A. N. A., & Wisan, A. B. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1007169
Ernest, D. K., Collier, A., Chandrasekhar, A., Xie, L., Darraji, S., Patel, J. R., Almandoz, J. P., & Messiah, S. E. (2025) · Women s Health Reports · doi:10.1089/whr.2024.0143 · Cited by 4
“39 Additionally, hyperinsulinemia ampli fi es LH-induced androgen production in adipose cells and reduces the synthesis of SHBG in the liver, 40 thus promoting higher plasma concentrations of androgens, 41 another suspected cause of metabolic complication related to PCOS.”
Soni, A., Parikh, M., & Gandhi, T. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22300-6.00013-9
Addressing a Key Metabolic Component of PCOS: Insulin
Hopkins, D., & Chappell, A. (2025) · Obstetrics and gynecology. · doi:10.5772/intechopen.1010981
Polycystic ovary syndrome: new trends in diagnosis and treatment
Абусуевна, А. З., Лукмановна, С. К., Efendieva, R. M., Амлетовна, С. Н., & Ibragimov, B. (2025) · Translational Medicine · doi:10.18705/2311-4495-2025-12-2-161-170
Environmental Chemicals and Risk of Polycystic Ovary Syndrome (PCOS)
Javed, M., Suramya, S., Bhutto, H. N., Shahid, S., Saifi, M. A., Ahmad, S., & Raisuddin, S. (2025) · Springer eBooks · doi:10.1007/978-981-95-0575-3_2
Nutritional management in polycystic ovary syndrome
Bisht, S., Nandave, M., Singh, M. F., Bisht, L., & Kumar, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34003-1.00010-9
Branched-chain amino acid transferase 2 (BCAT2) deficiency: A case series and systematic review
Filipic, M., Remec, Ž. I., Torkar, A. D., Šuštar, N., Čuk, V., Rodaro, C., Debeljak, M., Mlinarič, M., Šikonja, J., Silva, V. B., et al. (2026) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2026.101291
“Notably, in Cases 1 and 2, other, more common contributors to insulin resistance were observed, including obesity in both cases and PCOS in Case 1 [27].”
Ye, J., Cen, S., Qi, Q., Wang, C., Wang, J., Wang, J., Yaping, G., & Wang, J. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02158-x
“This also affects ovarian function [10].”
王, 月. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.162501
Erkal, N., & Mayir, Y. A. (2026) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/ceog46000
Ebrahimi, A. H., Shakib, P., Yavari, F., Sharafi, Z., Morovvati, A., Zarei, M. R., Dirbaziyan, A., & Movahhed, T. K. (2026) · Journal of Education and Health Promotion · doi:10.4103/jehp.jehp_1612_24
“[7] Examples of studied genes in insulin signaling pathways include IRS1, IRS2, AKT2, INSR, GSK3B, PPP1R3, PTP1B, and SORBS1.”
Huang, S., Chen, S.-R., Chen, W.-H., Zheng, L., Xu, J. Q., Shi, Y., Lin, S., & Shi, Q. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70249 · Cited by 3
Stolarska, K., Gaj-Hunter, A., Rędziniak, P., Ruzik, A., Rajs, M., Przebieradło, P., Żak, S., Kowalska, M., Żurek, K., & Terpiłowska, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5971
Assessment of Corin and Neprilysin in Diverse Polyendocrine Metabolic Ovarian Syndrome Presentations
Fleih, M. H., El-Yaseen, H. D., & Al-Naddawi, A. M. (2026) · Journal of the Faculty of Medicine Baghdad · doi:10.32007/jfacmedbaghdad3314
Kobayashi, H. (2026) · Reproductive Sciences · doi:10.1007/s43032-026-02191-8
“In PMOS, mTOR functions as a central hub integrating insulin–IGF-1 signaling and IRS-related pathways, regulating cellular proliferation, steroidogenesis, metabolic homeostasis, and autophagy through activation of the PI3K–AKT pathway and inhibition via the AMPK [20, 21, 51–53 ].”
Roles and Biological Effects of Polysaccharides in Polycystic Ovary Syndrome: A Narrative Review
Ding, N., Sun, C., Wang, H., Lv, Y., Han, Y., & Kuang, H. (2026) · Reproductive Sciences · doi:10.1007/s43032-026-02232-2
Metadata
- Authors
- Herman, R., Sikonja, J., Jensterle, M., Janez, A., & Dolzan, V.
- Affiliations
- University of Ljubljana (SI)
- Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
- Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-02-05
- Volume
- 24
- Issue
- 4
- Pages
- 3140
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9962893
- OpenAlex
- W4319318242
- Cited by
- 69
- References
- 97
- Citations by year
- 2026: 16 · 2025: 25 · 2024: 16 · 2023: 12
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Slovenian Research Agency (ARRS) (P1-0170, P3-0298)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- polycystic ovary syndrome, insulin metabolism, insulin resistance, insulin secretion, insulin clearance, beta-cell function, hyperandrogenemia, insulin signaling, PCOS pathogenesis
- MeSH terms
- Female, Humans, Insulin, Insulin Resistance, Polycystic Ovary Syndrome, Signal Transduction, Hyperandrogenism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.